Lonza and Oxford Nanopore collaborate to advance mRNA Therapeutics
The significance of mRNA technology has been highlighted in recent years, particularly with its role in rapidly developing and bringing COVID-19...
2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
NDM Pharma provides POC for NMD670
In Science Translational Medicine the team headed by Thomas Holm Pedersen from NDM Pharma A/S report that they have conducted animal studies and a...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...
AstraZeneca to take over Fusion Therapeutics Inc
Fusion Pharmaceuticals Inc‘s acquisition for US$2bn upfront marks a major step forward in AstraZeneca delivering on its ambition to transform cancer...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...